Core Insights - Shanghai's biopharmaceutical industry is experiencing significant growth, projected to reach a scale of 1 trillion yuan by 2024, with a compound annual growth rate of 8.94% from 2021 to 2024 [1] - The emergence of the biopharmaceutical sector marks Shanghai's fifth trillion-yuan industry cluster, alongside electronics, automotive, high-end equipment, and software [1] - The city is focusing on three leading industries: artificial intelligence, integrated circuits, and biopharmaceuticals, which are becoming new economic pillars [1] Industry Growth - The manufacturing output of Shanghai's biopharmaceutical sector is also impressive, increasing from 171.2 billion yuan in 2021 to 201.17 billion yuan in 2024, with a compound annual growth rate of 6.9% [1] - By 2025, Shanghai aims to establish a world-class biopharmaceutical industry cluster, including six industrial parks each exceeding 10 billion yuan in scale [1] R&D and Innovation - From 2021 to August 2025, Shanghai has approved 30 domestic Class I innovative drugs, accounting for 17% of the national total, and 4 products in cell and gene therapy, representing 57% of the national market [2] - The city has also approved 45 Class III innovative medical devices, making up 20% of the national total, showcasing strong collaborative innovation between industry, academia, and research [2] - Shanghai's publication volume in top-tier life sciences journals has increased, with 93 articles in journals like "Cell," "Nature," and "Science" last year [2] Investment and Policy - In 2024, Shanghai established a biopharmaceutical mother fund with a total scale of 22.5 billion yuan, selecting 13 sub-funds and amplifying the capital scale by 5.59 times [3] - The city has also set up a 10 billion yuan merger and acquisition fund targeting key areas such as traditional Chinese medicine and vaccines [3] - Shanghai's biopharmaceutical sector has attracted cumulative financing of 238.37 billion yuan from 2021 to 2024, leading the nation [3] Ecosystem and Future Outlook - Shanghai hosts a complete ecosystem of multinational pharmaceutical companies, with 2,183 regulated biopharmaceutical enterprises as of 2024, including 19 of the top 20 global pharmaceutical and medical device companies having headquarters or R&D centers in the city [2] - The city's innovative policies and comprehensive ecosystem are driving the biopharmaceutical industry towards a trillion-yuan scale, representing a model for urban industrial upgrading [3]
上海生物医药产业规模将破万亿元
Zhong Guo Xin Wen Wang·2025-10-25 05:59